Calls for proposals
Drug available for combination trials
The Cancer Research UK's Combinations Alliance and the NIHR CRN Industry Alliance are collaborating to support access to novel agents
We invite researchers from both the ECMC and NIHR networks to submit novel proposals involving the novel drug below with standard of care chemotherapy and/or radiotherapy and/or another novel drug. An overview of the benefits, expectations and framework for resarchers can be found on the researchers page with the details of this call below.
Applications will be prioritised based on scientific and clinical merit, alignment with CRUK's Statement of Intent and fit with the core development program of the drug.
|Mode of Action||Drug||Company||Webinar date||Primary contact|
- Review the drug on offer by reading the <data pack> and consider a novel proposal involving another drug, chemotherapy or radiotherapy
- Read the guidelines
- Attend the webinar by contacting CombinationsAlliance@cancer.org.uk
- Submit the non-confidential EOI form to CombinationsAlliance@cancer.org.uk
EOIs are reviewed in a two-stage process; closed review followed by face-to-face workshop and successful applicants will apply via CRUK’s Clinical Research Committee CRC.
Trial open expectation is within 12 months of CRC meeting.
|EOI submission deadline|
|F2F workshop for invited applicants|
|CRC submission deadline > 500k||
Primary: 19 March 2019
Secondary: July 2019
|CRC submission deadline < 500k||Early June 2019|
|CRC meeting||Nov 2019|
|Trial open||Nov 2020|
EOI calls are made twice a year, dependent on partner offerings, via the ECMC network. Our formal EOI calls are driven by the Clinical Research Committee Meeting schedule via the Clinical Trial Awards.
Early phase combination proposals involving the offered novel drug with either another novel drug, chemotherapy or radiotherapy are welcome and will be prioritised based on scientific and clinical merit and fit with the core development program of the drug.
EOIs submitted outside of these formal EOI calls are welcomed and reviewed on an ad hoc basis. We encourage you to contact us with your novel combination ideas outside the formal rounds and if you would like to be added to the direct ECMC distribution list please email us your request.